Do you want to read an article? Please log in or register.
Navigating the Evolving Treatment Paradigm for Advanced EGFR-mutated NSCLC
Lung, Respiratory and Thoracic Cancer
SPECIAL REPORT
Related content
ELCC 2024
Lung, Respiratory and Thoracic Cancer
MARIPOSA-2: Improved post-progression outcomes with amivantamab plus chemotherapy in EGFR-mutated advanced NSCLC
ELCC 2024
Lung, Respiratory and Thoracic Cancer
FLAURA2: Frontline osimertinib plus chemotherapy in patients with EGFR-mutated advanced NSCLC
ELCC 2024
Lung, Respiratory and Thoracic Cancer
FLAURA2: Safety data support osimertinib plus chemotherapy as a beneficial frontline therapy for patients with EGFR-mutated advanced NSCLC
Lung, Respiratory and Thoracic Cancer
Longitudinal Analyses of Circulating-Tumor DNA for Detection of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Progression During Treatment: Data From FLAURA and AURA3
J Thorac Oncol
Gray JE, Markovets A, Reungwetwattana T, Majem M, Nogami N, Peled N, Lee JS, Cho BC, Chewaskulyong B, John T, Han JY, Sebastian M, Todd A, Rukazenkov Y, Barrett C, Chmielecki J, Lee SM, Ramalingam SS, Hartmaier R
doi: 10.1016/j.jtho.2024.07.008
ELCC 2024
Lung, Respiratory and Thoracic Cancer
FLAURA2: Osimertinib plus chemotherapy provides long-term benefits in post-progression outcomes versus osimertinib alone in EGFR-mutated advanced NSCLC
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Lu S, Zhang Y, Zhang G, Zhou J, Cang S, Cheng Y, Wu G, Cao P, Lv D, Jian H, Jin X, Chen C, Tian P, Wang K, Jiang G, Chen G, Chen Q, Zhao H, Ding C, Guo R, Sun G, Wang B, Jiang L, Liu Z, Fang J, Yang J, Zhuang W, Liu Y, Zhang J, Pan Y, Chen J, Yu Q, Zhao M, Cui J, Li D, Yi T, Yu Z, Yang Y, Zhang Y, Zhi X, Huang Y, Wu R, Chen L, Zang A, Cao L, Li Q, Li X, Song Y, Wang D, Zhang S, Ding L, Zhang L, Ji D, Shen Z
doi: 10.1016/j.lungcan.2024.107901
Lung, Respiratory and Thoracic Cancer
Prevalence of EGFR Mutations in Patients With Resected Stage I-III NSCLC: Results From the EARLY-EGFR Study
J Thorac Oncol
Soo RA, Reungwetwattana T, Perroud HA, Batra U, Kilickap S, Tejado Gallegos LF, Donner N, Elsayed M, Huggenberger R, Van Tu D
doi: 10.1016/j.jtho.2024.06.008
SABCS 2024
Breast Cancer
Advancing Breast Cancer Treatment with Elacestrant
ESMO 2024
Lung, Respiratory and Thoracic Cancer